Maggie Bywater Ekegärd, MD, M.Sc.
Senior Advisor, Business Development
Educated in Pathology and Molecular Biology in Uppsala University, Sweden, Maggie is a senior executive with extensive experience in building biotechnology and life science-related businesses. Accomplished in identifying and commercializing technologies, as well as successfully bringing new classes of products to market in global biotech industry, she has extensive experience of start-up biotech companies and managing growth in small businesses, as well as in global organizations. A business developer and deal maker with over thirty years of industry experience in integration of technologies to answer difficult biological questions, she knows genomics, diagnostics, drug discovery and functional biology systems. Maggie has international experience in new product development for human health and agricultural biologicals markets. Maggie Bywater has spent her career in the business world identifying and establishing proprietary technologies; developing and manufacturing leading edge products; and developing markets to bring these products quickly to market. Maggie is passionate about the commercialization of novel technologies to advance the rapid application of research to society. She has never been afraid of a challenge, andenjoys patent and regulatory strategy.
Jennifer Moody, PhD
Jennifer brings to Morphocell 13 years of business and operations management in regenerative medicine, spanning the commercial development of reagents through to cell based therapeutics. Jennifer obtained a BSc in genetics from York University (Toronto), a PhD in Genetics from UBC (Vancouver), and pursued postdoctoral studies in Lund, Sweden. At STEMCELL Technologies in Vancouver she led commercial development of the TeSR product line. At the Centre for the Commercialization of Regenerative Medicine (CCRM) in Toronto she functioned in operations, alliance management and business development roles. At BlueRock Therapeutics she was instrumental in establishing the company’s pluripotent stem cell platform to enable its clinical programs. Jennifer is a member of ISSCR and ISCT, serves on the ISCT Business Model and Investment subcommittee and is a member of the Rotman Business School Healthcare and Life Sciences Leadership Network. Jennifer served as COO of Morphocell until December 2020 and is now Director of Market Development, Gene Therapy at Pall Corporation.
Kobas & Kobas CPA
Senior Advisor, Finance
Senior Advisor, Legal
Osler, Hoskin, Harcourt LLP